KHRISTINA MEISSNER: Open Payments
NPI 1982018123 · MONTPELIER, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$416 in 19 payments from 11 companies in 2025. Trend: 2023 $228 · 2024 $236 · 2025 $416
Food & beverage: $416
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 5 | $129 |
| Novo Nordisk Inc | 3 | $48 |
| Reprise Biomedical, Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $43 |
| Astellas Pharma US Inc | 1 | $32 |
| Exact Sciences Corporation | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| HARMONY BIOSCIENCES LLC | 1 | $19 |
| PFIZER INC. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
Products named: Qelbree, Miro3D, QULIPTA, Veozah, Ozempic, Cologuard Collection Kit, TRINTELLIX, WAKIX.
Industry payments across ID — which companies pay providers there.
